TriSalus Life Sciences (TLSI) Notes Payables (2021 - 2023)

TriSalus Life Sciences' Notes Payables history runs 3 years deep, the most recent figure standing at $10.0 million for Q2 2023.

• On a quarterly basis, Notes Payables rose 964.3% year-over-year to $10.0 million in Q2 2023; TTM through Jun 2023 was $10.0 million, a 964.3% increase from a year earlier, with the FY2022 full-year figure at $2.5 million, up 350.74% from the prior year.
• Notes Payables climbed to $10.0 million in Q2 2023 per TLSI's latest filing, from $4.7 million in the prior quarter.
• Across five years, Notes Payables topped out at $10.0 million in Q2 2023 and bottomed at $544000.0 in Q4 2021.
• The 3-year median for Notes Payables is $944000.0 (2022), against an average of $2.9 million.
• Across the five-year window, Notes Payables surged 350.74% in 2022 and jumped 964.3% in 2023, its largest moves.
• Year by year, Notes Payables stood at $544000.0 in 2021, then jumped by 350.74% to $2.5 million in 2022, then soared by 309.75% to $10.0 million in 2023.
• Per Business Quant, the three latest TLSI Notes Payables figures stand at $10.0 million (Q2 2023), $4.7 million (Q1 2023), and $2.5 million (Q4 2022).